Climb Bio, Inc.
CLYM
$1.21
-$0.02-1.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 138.60% | 55.84% | -1.56% | -37.94% | -54.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 486.77% | 266.54% | 153.27% | 110.47% | -57.58% |
| Operating Income | -486.77% | -266.54% | -153.27% | -110.47% | 57.58% |
| Income Before Tax | -540.10% | -110.42% | -76.15% | -42.80% | 73.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -540.10% | -110.42% | -76.15% | -42.80% | 73.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -540.10% | -110.42% | -76.15% | -42.80% | 73.26% |
| EBIT | -486.77% | -266.54% | -153.27% | -110.47% | 57.58% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -344.98% | -62.22% | -44.56% | -26.56% | 74.02% |
| Normalized Basic EPS | -360.05% | -194.76% | -138.53% | -94.20% | 65.84% |
| EPS Diluted | -344.98% | -62.22% | -44.51% | -26.53% | 74.03% |
| Normalized Diluted EPS | -360.05% | -194.76% | -138.53% | -94.20% | 65.84% |
| Average Basic Shares Outstanding | 110.44% | 75.78% | 42.86% | 6.18% | 3.40% |
| Average Diluted Shares Outstanding | 110.44% | 75.78% | 42.86% | 6.18% | 3.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |